Tackling resistance: Emerging antimalarials and new parasite targets in the era of elimination

Audrey R. Odom John, Emily S. Mathews

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Malaria remains a significant contributor to global human mortality, and roughly half the world's population is at risk for infection with Plasmodium spp. parasites. Aggressive control measures have reduced the global prevalence of malaria significantly over the past decade. However, resistance to available antimalarials continues to spread, including resistance to the widely used artemisinin-based combination therapies. Novel antimalarial compounds and therapeutic targets are greatly needed. This review will briefly discuss several promising current antimalarial development projects, including artefenomel, ferroquine, cipargamin, SJ733, KAF156, MMV048, and tafenoquine. In addition, we describe recent large-scale genetic and resistance screens that have been instrumental in target discovery. Finally, we highlight new antimalarial targets, which include essential transporters and proteases. These emerging antimalarial compounds and therapeutic targets have the potential to overcome multi-drug resistance in ongoing efforts toward malaria elimination.

Original languageEnglish
Article number1170
StatePublished - 2018


  • Antimalarial
  • Drug discovery
  • Drug targets
  • Plasmodium
  • Resistance


Dive into the research topics of 'Tackling resistance: Emerging antimalarials and new parasite targets in the era of elimination'. Together they form a unique fingerprint.

Cite this